$5.26
-2.95%
N/A-$0.16
보건 의료
제약 제조업체 - 전문의약품 & 제네릭
NASDAQ
활발히 거래 중
InterCure Ltd.는 그 자회사를 포함하여 의료용 대마 제품의 전 생애주기 전반에 적극적으로 관여하고 있습니다. 이는 초기 연구와 재배부터 제조, 마케팅, 글로벌 유통에 ...
A
Alexander Rabinovich
InterCure Ltd.
나이 55재임 기간 7y핵심 인물 리스크: High
Alexander Rabinovich has proven highly effective at building InterCure into a credible, vertically integrated cannabis player, successfully scaling operations over the last several years. However, investors must weigh this growth...
핵심 위험
•High key-man risk due to centralized CEO/Chairman role
•Ongoing stock price and liquidity volatility
•Regulatory uncertainty in international cannabis markets
핵심 순풍
•Consistent revenue growth and scaling operational capacity
•Successful implementation of a vertically integrated business model
•Expansion into new international markets
A
Alexander Rabinovich
InterCure Ltd. (INCR) · NASDAQ / TASE
Israeli나이 55재임 기간 7 년창업자 CEO핵심 인물 리스크: High
Not publicly disclosed in detail
출신 배경
Alexander Rabinovich founded InterCure to build a vertically integrated pharmaceutical-grade cannabis powerhouse, scaling the company from early-stage operations to international market leadership.
첫 기회: Pioneering the Israeli medical cannabis market as a veteran leader in the sector.
CEO가 되기까지: Rabinovich led InterCure through its transformation into a public entity, serving as CEO since January 2019, and was appointed Chairman in 2025 to solidify control.
초기 비전: To establish a global, vertically integrated, pharmaceutical-grade cannabis company.
Alexander Rabinovich has been the driving force behind InterCure's growth for over a decade. Starting as a pioneer in the Israeli medical cannabis space, he successfully led the company through its public listing and subsequent expansion. His leadership has been characterized by aggressive international partnership building and the execution of a 'seed-to-sale' business model. Following five years of CEO tenure, he took on the role of Chairman in 2025 to oversee the company's long-term strategy while maintaining executive oversight.
founder-ledcannabis-pioneervertically-integrated
투자 관점
Alexander Rabinovich has proven highly effective at building InterCure into a credible, vertically integrated cannabis player, successfully scaling operations over the last several years. However, investors must weigh this growth...
긍정 요인
Consistent revenue growth and scaling operational capacity
Successful implementation of a vertically integrated business model
Expansion into new international markets
핵심 리스크
High key-man risk due to centralized CEO/Chairman role
Ongoing stock price and liquidity volatility
Regulatory uncertainty in international cannabis markets
경력
Rabinovich has focused his professional energy primarily on scaling InterCure Ltd. and its subsidiary Canndoc into a global cannabis leader.
InterCure Ltd.
이니셔티브: CEO & Founder
기간: 2019–Present
사건: Led IPO, expanded international distribution, built vertical integration.
결과: Navigated significant stock price volatility and the broader cannabis industry downturn.
serial-founder
회사 성과
InterCure has achieved significant revenue growth under Rabinovich but has faced challenging stock performance amid broader market volatility.
매출: Reported NIS 270 million in revenue for 2025, demonstrating substantial scaling since his tenure began.
수익성: Achieved positive adjusted EBITDA, though net losses persist as the company balances growth with operating costs.
주가: The stock has faced downward pressure, consistent with broader cannabis sector challenges, significantly off its historical highs.
•International expansion partnerships
•Successful integration of Botanico
•Consistent revenue growth
•Significant stock price decline since public listing
•Ongoing regulatory complexities in global cannabis markets
growth-focusedvolatile-stock
경영 역량
Rabinovich acts as a hands-on operator who is deeply involved in financing and strategic M&A decisions.
스타일: Hands-on operator
Rabinovich maintains a high level of executive control, often leading financing rounds himself to demonstrate personal alignment with the company. He focuses on building a vertically integrated organization, prioritizing operational control from cultivation to distribution. His management style is viewed as highly focused on execution and aggressive expansion, though it sometimes raises questions regarding corporate governance.
hands-oncentralized-control
자본 배분
Capital allocation is driven by aggressive expansion and vertical integration, occasionally requiring dilutive private placements.
Focuses on achieving operating scale, sometimes prioritizing top-line growth over immediate profitability.
Botanico acquisition: Expanded U.S. market access; ongoing.
Rabinovich employs an aggressive capital allocation strategy, frequently seeking growth through both organic expansion and tactical acquisitions. His commitment to the company is evidenced by his direct participation in private equity placements, which signals confidence to investors, although these moves are sometimes viewed with caution due to governance considerations regarding executive control.
aggressive-m&acapital-intensive
자금 조달 및 파이낸싱
Demonstrates consistent ability to access capital markets, often through private placements, while personally investing in the company.
Private Placement · NIS 22M (with potential for NIS 54M): Used for global expansion; participation by the CEO noted by the market.
희석: Significant; frequent capital raises have impacted existing shareholder equity.
Rabinovich is highly active in fundraising, demonstrating strong relationships with pharma-focused hedge funds. His personal participation in these rounds is designed to boost investor confidence, though the frequent use of equity-linked instruments has caused dilution. Financing strategy remains critical to the company's ongoing global expansion goals.
dilutiveinvestor-focused
지배구조 및 통제
The CEO maintains high levels of control, further solidified by his 2025 appointment as Chairman.
주식 클래스 상세: Not explicitly detailed, but governance is highly centralized under the CEO-Chairman role.
Governance is characterized by high centralization under Alexander Rabinovich. His dual role as CEO and Chairman of the Board consolidates his control over the company's direction. While this structure ensures rapid decision-making, it has been noted as a potential risk factor by some observers regarding minority shareholder alignment.
centralized-powergovernance-risk
건강 및 승계
No public concerns regarding health; succession is tied to his centralized control.
건강 상태: No public concerns
승계 계획 공시: 아니오
핵심 인물 리스크: High
Rabinovich's dual role as CEO/Chairman creates high key-man risk, with no clear publicly announced successor.
key-man-risk
R&D 및 기술 비전
Innovation is focused on pharmaceutical-grade cannabis production technology and genetic research.
Ongoing commitment to R&D for medical cannabis cultivation.
Vertical integration of 'seed-to-sale' tech: Ongoing; provides operational efficiencies.
High focus on standardization and clinical-grade requirements.
•Early focus on international medical cannabis markets outside the U.S.
Rabinovich prioritizes R&D that supports clinical-grade cannabis production and scalable cultivation technologies. His long-term vision emphasizes proprietary research and genetics, aiming to differentiate InterCure from competitors that focus solely on retail or commoditized cannabis products.
tech-focused
인재 채용
Successfully attracting industry talent and integrating leadership from M&A activities.
ISHI Founders: Brought U.S. market expertise and technology integration.
Strong, with an emphasis on operational and international expertise.
유지율: Strong
Rabinovich builds his leadership team by integrating talent from strategic acquisitions and bringing in experienced industry professionals. This approach ensures the company retains specialized knowledge in technical and geographic focus areas, supporting the overarching global strategy.
talent-acquisition
강점
Rabinovich’s primary strength is his unwavering focus on scaling the company as a vertically integrated industry leader.
Strategic Vision: Consistently pivoting the company towards high-growth international medical cannabis opportunities.
Operational Execution: Scaling production capabilities to meet pharmaceutical-grade standards.
strategicoperational-focus
약점 및 실패
Governance concerns and stock price volatility represent the most significant criticisms of his tenure.
Governance
Centralization of power as CEO and Chairman creates potential conflicts.
예시: Participation in private placements.
Shareholder Returns
Inability to maintain share price despite business growth.
예시: Significant decline in market cap since listing.
governance-risk
마케팅 및 브랜드
The brand is positioned as a 'pharmaceutical-grade' leader, leveraging partnerships to drive market credibility.
Transitioned the brand from an Israeli producer to an international pharmaceutical cannabis player.
The marketing strategy focuses on quality and regulatory compliance, positioning products as pharmaceutical-grade to appeal to medical markets. The company uses strategic global partnerships to build brand trust and access international distribution channels, moving beyond standard consumer retail cannabis perceptions.
premium-positioningb2b-focus
PR 및 커뮤니케이션
Rabinovich maintains a high-profile, confident communication style, frequently utilizing press releases to signal strategic progress.
미디어 평판: Mixed
사건: Stock volatility and regulatory pressure
대응: Emphasized operational milestones and international expansion to maintain investor confidence.
Rabinovich is proactive in public communication, regularly highlighting record revenues and operational achievements. While he successfully communicates the long-term vision, his direct involvement in company financing occasionally sparks debate regarding governance and transparency among market analysts.
proactive-pr
상류 / 하류 / 대체 기업